Bioscience company Metabolix announced today the launch of a new office in Cologne, Germany, which opened its doors on April 16. The space, located in the BioCampus Cologne life science park, will give the company direct access to the European market for biopolymers and will be a coordination point for Metabolix's regional initiatives in renewable chemicals. The opening of this new office marks the company's first international expansion. The Cologne office will coordinate business development, customer service, and technical support for Metabolix's business partners and biopolymer customers in Europe.
With a growing focus on sustainability initiatives in the European Union, as well as decisive steps for increasing the adoption of green alternatives to conventional plastics and chemicals, opening a German office related to life science innovation will give Metabolix a central location from which to serve its customers and business partners.
The BioCampus Cologne park, established in 2002, is currently one of the largest biotechnology parks in Germany. It houses approximately 20 life science companies, including Bayer HealthCare, Sanofi-Aventis, and Direvo.
Information from the Freedonia Group indicates that worldwide demand for bioplastics is anticipated to more than triple through 2015, with Western Europe continuing to be the largest consumer of bioplastic materials. Metabolix has led the industry with more than 700 patents, both issued and pending, in developing its line of biopolymer resins marketed under the Mirel and Mvera brands, as well as bio-based industrial chemicals as "drop in" replacements for petroleum-based products. The Mirel and Mvera brands have the same physical properties as petroleum-based resins and can be processed on the same equipment with similar productivity and post-processing techniques, but Metabolix biopolymers have unique biodegradability properties.
Metabolix is a bioscience company specializing in the development of clean, sustainable solutions for plastics, chemicals, and energy. The company takes a systems approach - from gene to end product - and integrates advanced biotechnology with innovative industrial practice. The company is currently developing bio-sourced industrial chemicals and plastics, as well as a proprietary platform technology for co-producing plastics, chemicals, and energy from crops.
For more information, visit the company's Web site at metabolix.com
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net